UPDATE: Perspective Therapeutics Q2 EPS $(0.17) Beats $(0.21) Estimate, Sales $526.00K Beat $60.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Perspective Therapeutics (AMEX:CATX) reported Q2 EPS of $(0.17), beating the $(0.21) estimate, and sales of $526K, surpassing the $60K estimate. Despite a 50% improvement in EPS from last year, sales decreased by 10.54% year-over-year.
August 12, 2024 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Perspective Therapeutics (AMEX:CATX) reported better-than-expected Q2 EPS of $(0.17) and sales of $526K, significantly beating analyst estimates. However, sales decreased by 10.54% year-over-year.
The better-than-expected EPS and sales figures are likely to positively impact CATX's stock price in the short term. However, the year-over-year decline in sales may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100